Skip to main content
. 2016 Feb 24;11:9. doi: 10.1186/s13027-016-0056-y

Fig. 1.

Fig. 1

Cumulative incidence of HCC according to treatment outcome (SVR vs. non-SVR) with pegylated interferon alpha-2b and ribavirin. HCC, hepatocellular carcinoma; SVR, sustained virological response